Takeda Pharmaceutical Company Limited (TAK)
NYSE - Nasdaq Real-time price. Currency in USD
Add to watchlist
17.47+0.03 (+0.17%)
At close: 4:00PM EST
17.40 -0.07 (-0.40%)
After hours: 6:06PM EST
| Previous close | 17.44 |
| Open | 17.55 |
| Bid | 17.44 x 1800 |
| Ask | 17.48 x 2900 |
| Day's range | 17.06 - 17.50 |
| 52-week range | 12.43 - 20.00 |
| Volume | 3,181,302 |
| Avg. volume | 3,852,611 |
| Market cap | 55.752B |
| Beta (5Y monthly) | 1.11 |
| PE ratio (TTM) | 21.53 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 0.85 (4.80%) |
| Ex-dividend date | 29 Sep 2020 |
| 1y target est | N/A |
- Yahoo Finance
Coronavirus update: Merck to produce J&J vaccines; CDC launches vaccine finder
Merck (MRK) is stepping up to help Johnson & Johnson (JNJ) produce its COVID-19 vaccine, which was authorized last weekend.
- Zacks
Moderna's (MRNA) Coronavirus Vaccine Study Begins in Japan
Moderna's (MRNA) partner Takeda doses the first participant in a phase I/II study with Moderna's coronavirus vaccine candidate, mRNA-1273 in Japan.
- Motley Fool
Why Moderna Is Shooting Higher Today
Coronavirus stock Moderna (NASDAQ: MRNA) was up by nearly 8% in mid-afternoon trading on Thursday. Two pieces of news about the company's coronavirus vaccine seem to be supporting this rise. The first is Moderna's announcement that dosing of participants has begun in a phase 1/2 clinical trial for mRNA-1273 in Japan.
© 2021 Verizon Media. All rights reserved.
